Merck KGaA (OTCMKTS:MKGAF - Get Free Report) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $174.19 and traded as low as $166.98. Merck KGaA shares last traded at $167.55, with a volume of 93 shares trading hands.
Merck KGaA Trading Up 2.2 %
The company has a 50 day moving average of $174.19 and a 200 day moving average of $167.70. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.82 and a current ratio of 1.29. The stock has a market capitalization of $21.65 billion, a price-to-earnings ratio of 24.60 and a beta of 0.98.
Merck KGaA (OTCMKTS:MKGAF - Get Free Report) last posted its quarterly earnings data on Wednesday, May 15th. The company reported $1.74 EPS for the quarter, missing the consensus estimate of $1.92 by ($0.18). Merck KGaA had a net margin of 13.09% and a return on equity of 11.61%. The firm had revenue of $5.56 billion during the quarter. On average, research analysts predict that Merck KGaA will post 9.73 EPS for the current fiscal year.
Merck KGaA Company Profile
(
Get Free Report)
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
See Also
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
